Leading the Way to Precision Care: Molecular Diagnostics and Therapeutics in Lung Cancers. Mark G Kris, MD Memorial Sloan Kettering New Amsterdam USA
|
|
- Amberlynn Pierce
- 5 years ago
- Views:
Transcription
1 Leading the Way to Precision Care: Molecular Diagnostics and Therapeutics in Lung Cancers Mark G Kris, MD Memorial Sloan Kettering New Amsterdam USA
2 Molecular Therapeutics in Lung Cancers Financial Disclosures AstraZeneca - Consultant Additional Disclosures I was born a medical oncologist but was raised by thoracic surgeons I am a chemotherapy guy who has gone molecular
3 Molecular Therapeutics in Lung Cancers Introduction Revolution: targeting oncogenic drivers in lung cancers Growing opportunities from multiplex NGS testing New agents disrupt current standards: EGFR and ALK New Targets: NTRK, NRG, MET Expanding the use of targeted therapies Adjuvant Neoadjuvant Oligometastases and oligoprogression Intersection of targeted therapies with immunotherapeutics New research directions
4 Stage IV Lung Adenocarcinomas: Drug Therapy Response Rate 1 Year Survival 2 Year Survival No Chemotherapy 0% 10% 0% Single Agent 15% 20% 10% Two Drugs (Pemetrexed + Cisplatin) 25% 50% 18% Three Drugs 35% 35% 20% Two Drugs plus Bevacizumab 35% 51% 23% Pembrolizumab with >50% PD-L1 45% 70% Osimertinib with EGFR Exon 19/21 Mutation Alectinib with ALK Rearrangement Crizotinib with ROS1 Rearrangement 80% 90% 72% 83% 84% 75% 72% 85% 74%
5 Initial Gefitinib Investigators Meeting 14 July 1996 Jose Baselga Eric Rowinsky
6 Results with Gefitinib 250 mg Daily 6 FEB FEB 2002
7 Lung Cancer Mutation Consortium LCMC2 Oncogenic Drivers Aisner Clin Cancer Research 2018 N=423
8 LCMC1: Survival with the five most frequent oncogenic drivers SURVIVAL group=alk group=doub group=egfr(o) group=egfr(s) group=kras YEARS Altered Gene N Median Survival (95% CI) EGFR (sensitizing) years (2.7 to 5.4) Kris and Johnson JAMA 2014 EGFR (other) years (2.2 to 6.2) ALK years (3.0 to NA) KRAS years (1.9 to 3.6) Drivers in Two Genes years (1.6 to 4.6)
9
10 Marc Ladanyi Looking for a Target on Every Tumor Science 2009; 326: mag.org
11 Evolution of Multiplexed Testing Platforms Now-Gen MSK LC-MAP 8 genes Point mutations only Next-Gen MSK IMPACT 468 genes Point mutations plus deletions, insertions, amplifications Comparable cost
12 MSK-IMPACT DNA from FFPE Tumor and Normal cells Integrated Mutation Profiling of Actionable Cancer Targets Capture DNA for 410 cancer genes* Won H, et al., Journal of Visualized Experiments, Oct 2013 Cheng D, et al., J Mol Diagnostics, March 2015 Next-gen Sequencing ( x) Align to genome and analyze *As of February genes Somatic Mutations (Tumor-Normal Pairs): Base Substitutions Small Indels Copy Number Alterations Select Rearrangements
13
14 Landscape of Lung Cancers by NGS XXX XXX XXX XXX XXX XXX XXX Jordan Cancer Discov 2017
15 MSK-IMPACT : determinants of success Ryma Benayed
16 NGS Testing Using Cell free DNA from Plasma DNA fragments of bp with half life of ~2 hours Real-time, non-invasive, multilesions Cheaper because it does not require a biopsy Often very low amount of ctdna in the sea of wild type DNA - Needle in a farm Specific to tumor Diaz J Clin Oncol 2016
17 Concordance: Forty two patients had concurrent tissue NGS (42/86, 49% of MSK patients) Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (IMPACT) DNA isolated from tumor tissue and matched normal peripheral blood subjected to hybridization capture and deep-coverage NGS to detect somatic mutations in 468 cancer related-genes Mean overall coverage of sequencing depth ranged from X. Concordance Tissue vs Plasma 40/42 (95%) Plasma vs Tissue 26/42 (62%)
18 NGS results in patients with lung adenocarcinomas with no drivers with non-ngs testing Genomic alteration/s identified with no targeted therapy option No genomic alteration identified Sales Genomic alteration with targeted therapy in NCCN guidelines EGFR G719A BRAF V600E SOCS5-ALK CLIP4-ALK CD74-ROS1 KIF5B-RET KIF5B-RET CCDC6-RET Tumor from same procedure as tumor subjected to non-ngs testing yes yes yes yes yes yes no yes Patient s clinical course recently started erlotinib, response evaluation pending subsequently passed away disease shrinkage (<30%) with crizotinib partial response to crizotinib recently started crizotinib, response evaluation pending partial response to cabozantinib disease shrinkage (<30%) with cabozantinib candidate for cabozantinib after progression on chemotherapy 29% (n=9/31) 6% (n=2/31) 39% (n=12/31) 26% (n=8/31) Drilon Clin Cancer Res 2015 Genomic alteration with targeted agent available on or off a clinical trial CDKN2A Loss EGFR L747P EGFR exon 18 del (n=2) EGFR exon 20 ins ERBB2 L755F FGFR1 T141R KRAS G12C KRAS Q61H MDM2 Amp (n=3) Targeted therapeutic (clinicaltrials.gov number) with potential activity available at institution CDK4/6 inhibitor (NCT ) erlotinib, afatinib pan-erbb inhibitor (NCT ) pan-erbb inhibitor (NCT ) pan-erbb/mtor inhibitor (NCT ) FGFR inhibitor (NCT ) ERK inhibitor (NCT ) ERK inhibitor (NCT ) MDM2 inhibitor (NCT )
19 IFCT: Frequency of molecular alterations in six genes from 18,679 analyzed samples: overall population Barlesi Lancet 2016
20 Gallant Cancer Discov 2015
21 EGFR-KDD kinase domains (GLY 696-PRO 1370) Gallant Cancer Discov 2015
22 5 DECEMBER 2017
23
24
25 Strategies to Improve Outcomes in Patients with EGFR-mutant Lung Cancers Arbour and Riely Cancer 2018 (in press)
26 Components of care for patients with lung cancers with oncogenic drivers Targeted Therapies: Target Dependent and Independent Immunotherapy Surgery Angiogenesis Radiation Clinical Trials Chemotherapy
27 Small Cell Transformation + MET Amplification (1%) Small cell (1%) MET Amplification (3%) HER2 Amplification (8%) Unknown 18% The Stale Pie: Mechanisms of acquired resistance with 1 st and 2 nd generation EGFR TKIs T790M Alone 60% T790M + Small Cell (2%) T790M + MET Amplification (3%) T790M + HER2 Amplification (4%) Yu Clin Cancer Res 2013
28 Published online 7 May 2015 Acquired resistance to osimertinib and other 3rd generation agents in patients with acquired resistance to 1 st or 2 nd generation EGFR TKIs Published online 4 May 2015 Published online 1 May 2015
29 Genetic alterations associated with acquired resistance to osimertinib Target-dependent C797S G724S L718Q G796S/R/D L792F/H/Y The Pie in the Oven Target-independent MET amplification HER2 amplification HER2 exon 20 insertion EGFR amplification KRAS amplification KRAS G12S BRAF V600E MEK1 G128V JAK2 V617F FGFR3-TACC3 fusions small cell transformation
30 31 AUGUST 2017
31
32 TRK fusions found in diverse types of cancers Brain cancers (glioma, GBM, astrocytoma) Salivary (MASC) Thyroid cancer Lung cancer Secretory breast cancer Pancreatic Cholangiocarcinoma GIST Common cancer with low TRK fusion frequency Rare cancer with high TRK fusion frequency Colon Melanoma Sarcoma (multiple) Gliomas Thyroid cancer Infantile fibrosarcoma Congenital nephroma Spitz nevi Sarcoma (multiple) Estimated 1,500 5,000 patients harbor TRK fusion-positive cancers in the United States annually Hyman, LBA
33 Maximum change in tumor size (%) Larotrectinib efficacy regardless of tumor type * Thyroid Colon Melanoma Soft tissue sarcoma Lung GIST Appendix IFS Breast Salivary gland Cholangiocarcinoma Pancreas # Hyman, LBA
34 Science 2017
35 Garber Science 2017
36 CD74- NRG1 Fusion Activation of HER3-HER2 Autocrine Juxtacrine Fernandez-Cuesta Clin Can Res 2014
37 HER3 Inhibitors Fernandez-Cuesta Clin Can Res 2014
38 NRG1 Fusion Response to anti HER3 MAb 86 man with lung adenocarcinoma with CD74-NRG1 fusion detected by MSK-IMPACT. baseline week 11 Alexander Drilon MD, Thoracic Oncology Service
39
40 Ado-trastuzumab emtansine for patients with HER2 mutant lung cancers ORR was 44% (8/18, 95% CI 22-69%), study met primary endpoint.
41
42
43
44 Adjuvant Osimertinib EGFR-mutant Lung Cancers Proposed Phase III Study Design Stage IB IIIA EGFRm NSCLC (exon 19 del or L858R) Complete surgical resection No adjuvant chemotherapy Adjuvant chemotherapy N=660 Randomisation stratification: prior adjuvant chemotherapy, mutation type, stage 1:1 Osimertinib 80mg QD 3 year treatment Placebo 1 yr: DFS 2 yr: OS Trials are designed with Power = 90%, 2-sided alpha = 0.05 Based on enrolment rate of 23 patients/month, to be confirmed by detailed feasibility Assumes 35% death rate at time of DFS (50% maturity)
45 EGFR Resectable IB-IIIB (8 th ed) Enroll with local genotyping or ctdna LCMC 4.0 Neoadjuvant Precision Multimodality Therapy Osimertinib (Bivona) Crizotinib (Doebele) T-cell checkpoint inhibitor Chemotherapy Scans, Repeat ctdna Major pathologic response rate Correlates in persister cells Adjuvant therapy -investigator s choice followed by personalized strategies per future research studies
46 DNA Sequence Not The Whole Story DNA Sequencing Copy Number Changes Fusion Proteins Epigenome Gene expression profiling Proteome Thomas Lynch, MD
47 T-Cell Checkpoint Inhibitors in Patients with EGFR-mutant Lung Cancers Patients with EGFR-mutant lung caners excluded from pivotal clinical trials scant data Tumors with EGFR mutations generally have a low mutational burden. PR in 4%, PD-L1 >50% in 11%, high level TILs in 2% (Gainor Clin Cancer Res 2016) No consensus on what to do if a patient tumor has both EGFR mutation and PD-L1 > 50%. Some data Recommend frank discussion with the patient.favor PD-L1 drug 1 st.
48 WES is a challenge to apply as a diagnostic tool but targeted NGS is routinely used now and good estimate Variety of tumor types Same DNA libraries for both NSCLC only (Same tumor tissue in 80% cases) Zahir, Benayed, Nature Medicine 2017 Rizvi H, Sanchez-Vega, JCO [in press]
49 Direct use of TMB from targeted sequencing as a biomarker Rizvi H, Sanchez-Vega, JCO [in press]
50 Lessons learned from molecular revolution: Toward precision immunotherapy Don t discard low response rates in unselected patients just need to find the right population of people to give it to. Beatty, ASCO 2017
51 YES1 amplification: a new mechanism of acquired resistance to all EGFR kinase inhibitors in EGFR-mutant lung cancers YES1 is a Src family kinase (SFK) that phosphorylates YES1-associated protein 1 (YAP1), a Hippo pathway effector implicated in resistance to multiple targeted therapies Overexpression of YES1 a resistance mechanism in the EGFR-mutant PC9 lung adenocarcinoma cells by two different approaches: 1) generation of osimertinib-resistant cells through gradual dose escalation and 2) a forward transposon mutagenesis screen to recover afatinib-resistant PC9 derivatives Cells overexpressing YES1 exhibited resistance to all 3 generations of EGFR TKIs but sensitivity to SFK inhibitors Analysis of MSK-IMPACT data for 136 cases of acquired resistance to EGFR TKIs revealed 4 cases with YES1 amplification, 3 of which lacked other mechanisms of resistance Ichihara, Cancer Research 2017, Fan (MSK) submitted for publication
52 Characterization of drug-tolerant persister cells and adaptive resistance mechanisms in patients with EGFR-mutant lung adenocarcinomas treated with erlotinib or osimertinib MSK IRB # first on-treatment scan at 4 2 weeks Scan* subsequent scans every 8 2 weeks Scan* Scan* Scan* Day 0 Week TKI Therapy baseline scan & pre-treatment biopsy scan showing initial clinical response (ICR) 4 weeks biopsy of ICR* sample for pathology sample for whole-exome sequencing, RNAseq sample for pathology sample for wholeexome sequencing, RNAseq, and PDX Helena Yu, PI
53 Bending the survival curve in lung cancers Hellmann JAMA Oncology 2015 Stage IV Lung cancers - Today All Lung cancers - Tomorrow
54 There are no Good Prognosis Lung Cancers 8 th Edition T Stage (all N0M0) Primary Size (cm) N (%) 5 Year Survival Clinical Stage 5 Year Survival Pathological Stage T1a (8) 92% 92% T1b (31) 83% 86% T1c (24) 76% 81% T2a (19) 67% 74% T2b (6) 60% 65% T (8) 52% 57% T4 >7 403 (4) 38% 47% Rami-Porta J Thorac Oncol 2015
55 Components of Care for the Therapy for Lung Cancers Angiogenesis Clinical Trials Immunotherapy Targeted Rx Surgery Radiation Chemotherapy
56 Molecular Therapeutics in Lung Cancers Conclusions The discovery of oncogenic drivers and the identification of drugs to target them has transformed the care of persons with lung cancers Multiplex NGS testing at diagnosis permits the selection of the best initial targeted and immunotherapies New trial designs can accelerate progress across diseases Disease agnostic therapies have arrived more are on the way New therapies and paradigms have radically changed research priorities. Time to reboot. As we search for cures, we must meet the challenge to bring the best drug at the best time to each patient with lung cancer today
57 Kris Kris XXXXXXXXXXXXXXXXX Here's my sequence...
58 Response to Vemurafenib BRAF V600E Mutant Lung Cancer baseline 6 weeks on vemurafenib
59 When there are thousands of starfish and only one of you. What difference can you make throwing just one back in the water?
60 You can sure made a difference to this one
Adjuvant Therapies for Lung Cancers: New Directions
Adjuvant Therapies for Lung Cancers: New Directions Mark G Kris, MD Member and Attending Physician William and Joy Ruane Chair in Thoracic Oncology Memorial Sloan-Kettering Professor of Medicine, Weill
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationOTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento
OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento Dolores Isla Servicio de Oncología Médica HCU Lozano Besa de Zaragoza 2008 Selection Factors in Advanced NSCLC ( 8y ago)
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationExpanding Therapeutic Options for Cancer Patients with Comprehensive Profiling Alexander Drilon MD
Expanding Therapeutic Options for Cancer Patients with Comprehensive Profiling Alexander Drilon MD Clinical Director, Early Drug Development Service Memorial Sloan Kettering Cancer Center COI Disclosure
More informationThe oncologist s point of view: the promise and challenges of increasing options for targeted therapies in NSCLC
The oncologist s point of view: the promise and challenges of increasing options for targeted therapies in NSCLC Egbert F. Smit Department of Thoracic Oncology, Netherlands Cancer Institute, and Department
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationDisclosure of Relevant Financial Relationships NON-SMALL CELL LUNG CANCER: 70% PRESENT IN ADVANCED STAGE
MORPHOLOGY AND MOLECULAR TESTING IN NON-SMALL CELL OF LUNG NEW FRONTIEIRS IN CYTOPATHOLOGY PRACTICE American Society for Cytopathology San Antonio, Texas Sunday March 5, 2017 Disclosure of Relevant Financial
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationTargeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont. Masterclass 27 september 2018
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont Masterclass 27 september 2018 Outline Introduction EGFR TKI ALK TKI TKI for uncommon driver mutations Take home messages The promise of
More informationSupplementary Online Content
Supplementary Online Content Kris MG, Johnson BE, Berry LD, et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA. doi:10.1001/jama.2014.3741 etable 1. Trials
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationPersonalized Genetics
Personalized Genetics Understanding Your Genetic Test Results Tracey Evans, MD September 29, 2017 Genetics 101 Punnett Square Genetic Pedigree 2 Genetics 101 Punnett Square Genetic Pedigree 3 It s not
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationLung Cancer Update 2016 BAONS Oncology Care Update
Lung Cancer Update 2016 BAONS Oncology Care Update Matthew Gubens, MD, MS Assistant Professor Chair, Thoracic Oncology Site Committee UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Consulting
More informationTargeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation
Targeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation James Chih-Hsin Yang, MD, PhD National Taiwan University Hospital National Taiwan University Cancer Center Taipei, Taiwan
More informationIntegration of Genomics Into Clinical Pathways. Precision Medicine and Decision Support
Integration of Genomics Into Clinical Pathways Precision Medicine and Decision Support Faculty Andrew Hertler, MD, FACP Chief Medical Officer New Century Health Andrew Hertler, MD, FACP is employed by
More informationPersonalized Treatment Approaches for Lung Cancer
Personalized Treatment Approaches for Lung Cancer California Thoracic Society 2018 Annual Carmel Conference January 27, 2018 Matthew Gubens, MD, MS Associate Professor of Medicine Chair, Thoracic Oncology
More informationMET skipping mutation, EGFR
New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationState of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
More informationInhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS
Inhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS Driver Mutations to Classify Lung Cancer Unknown 36% KRAS 25% EGFR 15% ALK 4% HER2 2% Double Mut 2% BRAF 2% PIK3CA
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationTargeted Therapy for NSCLC: EGFR and ALK Fadlo R. Khuri, MD
EGFR and ALK Fadlo R. Khuri, MD President, American University of Beirut Professor of Medicine July 26, 2018 A great year end! Targeted Therapy for NSCLC: Evolving Landscape of Lung Adenocarcinoma NSCLC
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationCase Studies. Ravi Salgia, MD, PhD
Case Studies Ravi Salgia, MD, PhD Professor and Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Associate Director for Clinical Sciences Research City of Hope 04-21-2018 Objectives
More informationGiorgio V. Scagliotti Università di Torino Dipartimento di Oncologia
Giorgio V. Scagliotti Università di Torino Dipartimento di Oncologia giorgio.scagliotti@unito.it Politi K & Herbst R. Clin. Cancer Res. 2015; 21:2213 Breast Colorectal Gastric/GE Junction Tumor Type Head
More informationDrug Resistance in ALK- and ROS1-Rearranged Lung Cancers. Alice T. Shaw, MD PhD Director, Center for Thoracic Cancers September 16, 2017
Drug Resistance in ALK- and ROS1-Rearranged Lung Cancers Alice T. Shaw, MD PhD Director, Center for Thoracic Cancers September 16, 2017 ALK and ROS1 are Related Tyrosine Kinases, and Both are Targeted
More informationNSCLC 2 nd and further line therapies. Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute
NSCLC 2 nd and further line therapies Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute e.smit@nki.nl ESMO Guidelines 2016: Treatment of Stage IV nonsquamous NSCLC at progression
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationPersonalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader
Personalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader Agenda PHC Approach Provides Better Patient Outcome FMI offers Comprehensive Genomic Profiling,
More informationOptimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
More informationLUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
More informationComprehensive Genomic Profiling, in record time. Accurate. Clinically Proven. Fast.
Comprehensive Genomic Profiling, in record time Accurate. ly Proven. Fast. PCDx advantages Comprehensive genomic profiling, in record time PCDx Comprehensive Genomic Profiling (CGP) provides precise information
More informationPersonalized Therapies for Lung Cancer. Questions & Answers
Personalized Therapies for Lung Cancer Questions & Answers What are Personalized Therapies for lung cancer? Like people, no two lung cancer tumors are the same. Personalized medicine (also known as precision
More informationTissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~
16 th Dec. 2016. ESMO Preceptorship Program Non-Small-Cell Lung Cancer @Singapore Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~ Research Institute for Disease of
More informationCirculating Tumor DNA in GIST and its Implications on Treatment
Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna
More informationActivity of osimertinib and the selective RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement.
Activity of osimertinib and the selective RET inhibitor in an EGFR-mutant patient with acquired RET rearrangement. Z Piotrowska 1, H Isozaki 1, JK Lennerz 1, S Digumarthy 1, JF Gainor 1, N Marcoux 1, M
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationLung Cancer Biomarkers: A Practical Update
Lung Cancer Biomarkers: A Practical Update Lynette M. Sholl, M.D. Associate Pathologist, Brigham and Women s Hospital Associate Professor, Harvard Medical School Boston, MA Disclosures Consultant for Foghorn
More informationRXDX-101 & RXDX-102. Justin Gainor, MD February 20 th, 2014
RXDX-101 & RXDX-102 Justin Gainor, MD February 20 th, 2014 Background Chromosomal fusions are important oncogenic drivers in NSCLC - ALK Rearrangements (4-6%) - ROS1 Rearrangements (1-2%) - RET Rearrangements
More informationDisclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
More informationNGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation
NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation Michael R. Rossi, PhD, FACMG Assistant Professor Division of Cancer Biology, Department of Radiation Oncology Department
More informationNext generation diagnostics Bringing high-throughput sequencing into clinical application
Next generation diagnostics Bringing high-throughput sequencing into clinical application Leonardo A. Meza-Zepeda, PhD Translational Genomics Group Institute for Cancer Research Leonardo.Meza-Zepeda@rr-research.no
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More information1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?
Frequently Asked Questions (FAQs) in regard to Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors 1. Q: What has changed from the draft recommendations
More informationMP Circulating Tumor DNA Management of Non-Small-Cell Lung Cancer (Liquid Biopsy)
Medical Policy BCBSA Ref. Policy: 2.04.143 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Medicine Related Policies 2.04.121 Miscellaneous Genetic and Molecular Diagnostic Tests 2.04.45 Molecular
More informationStrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient
StrandAdvantage Tissue-Specific Cancer Genomic Tests Empowering Crucial First-Line Therapy Decisions for Your Patient Harness the power of precision medicine with StrandAdvantage Precision medicine in
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationDr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
More informationALCHEMIST. Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials
ALCHEMIST Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials What is ALCHEMIST? ALCHEMIST is 3 integrated trials testing targeted therapy in early stage lung cancer: l A151216:
More informationAdvances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie
Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Circulating Tumor DNA Management of Non-Small-Cell Lung Cancer (Liquid Biopsy) Page 1 of 36 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Circulating Tumor DNA
More informationCirculating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy)
Circulating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy) Policy Number: 2.04.143 Last Review: 1/2019 Origination: 1/2018 Next Review: 1/2020 Policy Blue Cross and Blue Shield
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationTumor mutational burden and its transition towards the clinic
Tumor mutational burden and its transition towards the clinic G C C A T C A C Wolfram Jochum Institute of Pathology Kantonsspital St.Gallen CH-9007 St.Gallen wolfram.jochum@kssg.ch 30th European Congress
More informationTARGETED THERAPY FOR LUNG CANCER. Patient and Caregiver Guide
TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Why Targeted Therapy?...2 Lung Cancer Basics...2 Changes in
More informationTargeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care
Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland
More informationOther Driver Mutations: cmet, B-RAF, RET, NTRK
Other Driver Mutations: cmet, B-RAF, RET, NTRK Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology and Medical Director, Memorial Cancer Institute Clinical Professor of Medicine Herbert Wertheim College
More informationMET as a novel treatment target- the story of the sleeping beauty. Balazs Halmos M.D. Montefiore Medical Center/Albert Einstein College of Medicine
MET as a novel treatment target- the story of the sleeping beauty Balazs Halmos M.D. Montefiore Medical Center/Albert Einstein College of Medicine MET as a novel treatment target MET as an oncogene MET
More informationSequencing in EGFR-Mutated NSCLC: Does Order Matter?
Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD,
More informationCorporate Medical Policy
Corporate Medical Policy Proteomic Testing for Targeted Therapy in Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteomic_testing_for_targeted_therapy_in_non_small_cell_lung_cancer
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationKEY FINDINGS 1. Potential Clinical Benefit in Non-Small Cell Lung Cancer with Gefitinib, Erlotinib, Afatinib due to EGFR E746_A750del. 2. Potential Cl
PATIENT INFO SAMPLE REFERING PHYSICIAN COPY TO (if different from ordering) Name: John Smith Date Collected: 10/23/2016 Name: Oncologist, M.D. Name: Pathologist, M.D. DOB: 04/22/1937 Date Received: 10/24/2016
More informationCell-free tumor DNA for cancer monitoring
Learning objectives Cell-free tumor DNA for cancer monitoring Christina Lockwood, PhD, DABCC, DABMGG Department of Laboratory Medicine 1. Define circulating, cell-free tumor DNA (ctdna) 2. Understand the
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationOsimertinib as first-line treatment of EGFR mutant advanced nonsmall-cell
Editorial Osimertinib as first-line treatment of EGFR mutant advanced nonsmall-cell lung cancer Chong-Kin Liam Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
More informationIndividualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy
Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy 1 st st International Oncological Conference Wrocław, October 6 th, 2012 Dr. Frank Kischkel Individualized Cancer Therapy:
More informationAVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect
More information1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance. 13/10/2017 Sara Redaelli
Dott.ssa Sara Redaelli 13/10/2017 1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance Tumor Heterogeneity: Oncogenic Drivers in NSCLC The Promise of Genotype-Directed Therapy
More informationLiquid biopsy: the experience of real life case studies
Liquid biopsy: the experience of real life case studies 10 th September 2018 Beatriz Bellosillo Servicio de Anatomía Patológica Hospital del Mar, Barcelona Agenda Introduction Experience in colorectal
More informationLiquid biopsy in lung cancer: The EGFR paradigm
Liquid biopsy in lung cancer: The EGFR paradigm Lynette M. Sholl, M.D. Brigham and Women s Hospital Dana Farber Cancer Institute Department of Pathology Boston, MA Disclosure of Relevant Financial Relationships
More informationUpdates in Lung Cancer
Updates in Lung Cancer J. Tanner Ringley, PharmD, BCOP, CPP Levine Cancer Institute Learning Objectives: Discuss incorporation of liquid biopsies into practice and interpretation of immunotherapy biomarker
More informationNew options for old and new targets in NSCLC Rosario García Campelo Medical Oncology Unit University Hospital A Coruña
New options for old and new targets in NSCLC Rosario García Campelo Medical Oncology Unit University Hospital A Coruña Phase II GOAL TRIAL DESIGN Key inclusion criteria Patients with locally advanced or
More informationPIK3CA mutations are found in approximately 7% of
Original Article Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas Juliana Eng, MD,*
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationUrinary ctdna Platform for Diagnosis and Cancer Treatment Monitoring. Summit August 19,2015
Urinary ctdna Platform for Diagnosis and Cancer Treatment Monitoring Mark G. Erlander, Ph.D., CSO CHI Next Generation Summit August 19,2015 Circulating Tumor DNA (ctdna) Tumor cells Main Advantages of
More informationIncorporating pharmacodynamic, response and patient selection biomarkers. Paul Elvin PhD Chief Translational Science Officer Aptus Clinical
Incorporating pharmacodynamic, response and patient selection biomarkers Paul Elvin PhD Chief Translational Science Officer Aptus Clinical 22 Oncology drug development Biomarkers key for: Strong hypothesis
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationRole of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney
Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor
More informationCDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018
CDx in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900 Research unit Versailles Saint-Quentin-en-Yvelines
More informationNCCN Non Small Cell Lung Cancer V Meeting July 8, 2016
NSCL 3 Submission from Myriad requesting the following statement to be listed as an additional high risk factor in footnote p : For lung ADC, a highrisk 46 gene molecular prognostic score determined by
More informationASCO Highlights and Controversies in advanced Lung Cancer. Torino, 11 giugno 2015
ASCO 2015 Highlights and Controversies in advanced Lung Cancer Torino, 11 giugno 2015 Paolo Bironzo AOU S Luigi Gonzaga - Orbassano Scuola di Specializzazione in Oncologia Medica Università di Torino What
More informationOsamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification
More informationNext-generation sequencing based clinical testing for lung cancer in Japan
Review Article Next-generation sequencing based clinical testing for lung cancer in Japan Masayuki Takeda 1, Kazuko Sakai 2, Kazuhiko Nakagawa 1, Kazuto Nishio 2 1 Department of Medical Oncology, 2 Department
More informationOTRAS DIANAS MOLECULARES TRATABLES. Rosario García Campelo Servicio de Oncología Médica Complejo Hospitalario Universitario A Coruña, CHUAC
OTRAS DIANAS MOLECULARES TRATABLES Rosario García Campelo Servicio de Oncología Médica Complejo Hospitalario Universitario A Coruña, CHUAC A propósito de un caso. Mujer 34 años Fumadora ocasional < 10
More informationEmerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC
Emerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC Keunchil Park, MD, PhD Samsung Medical Center, Sungkyunkwan University School of Medicine Faculty Disclosure Consulting
More informationNGS in tissue and liquid biopsy
NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences
More informationD Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
More informationPROGRESSION AFTER THIRD GENERATION TKI
PROGRESSION AFTER THIRD GENERATION TKI What next? National Cancer Center Hospital Yuichiro Ohe, MD Name of lead presenter Yuichiro Ohe employee of company and/or profit-making organization adviser of company
More informationBeyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy
Beyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy Oncogenic drivers in NSCLC Certain tumours arise as a result of aberrant activation
More informationFrequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R
Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB
More informationGenomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
More informationUpdates in Lung Cancer. J. Tanner Ringley, PharmD, BCOP, CPP Levine Cancer Institute
Updates in Lung Cancer J. Tanner Ringley, PharmD, BCOP, CPP Levine Cancer Institute Learning Objectives: Discuss incorporation of liquid biopsies into practice and interpretation of immunotherapy biomarker
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More information